GlassScriptPhysician profile
Armine Tadevosyan
NPI 1508488891
$3,637.59
in general payments reported to CMS, 2019-2025
21 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $55.13 · 2023: $987 · 2024: $743 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,469.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,193.59 | 2023-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $470.38 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $465.21 | 2023-2025 | |
| Ardelyx, INC. | $257.53 | 2024-2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $182.14 | 2025 | Gemtesa, Myfembree |
| Abbvie INC. | $174.01 | 2023-2025 | |
| Novo Nordisk INC | $172.16 | 2023-2025 | Wegovy, Saxenda, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.85 | 2025 | Jardiance |
| Angiodynamics, INC. | $112.50 | 2021 | |
| Dexcom, INC. | $90.18 | 2024-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $71.82 | 2025 | Tymlos |
| Pfizer INC. | $62.39 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $48.59 | 2025 | Gvoke Hypopen |
| Insulet Corporation | $35.30 | 2025 | Omnipod |
| Shield Therapeutics INC | $31.98 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $25.17 | 2025 | Tremfya |
| Ascensia Diabetes Care US INC. | $24.79 | 2023 | |
| Gilead Sciences, INC. | $23.58 | 2025 | |
| Esperion Therapeutics, INC. | $22.73 | 2025 | Nexletol |
| Nevro Corp. | $15.00 | 2023 | Senza |
| Acadia Pharmaceuticals INC | $13.69 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armine Tadevosyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.